Latest news with #Parodontax
Daily News Egypt
5 days ago
- Business
- Daily News Egypt
Haleon captures over 20% market share in Egypt, locally manufactures 90% of product portfolio
Haleon, the global consumer health leader, has reinforced its footprint in Egypt following its demerger from GSK in July 2022. The company now holds over 20% of Egypt's consumer health market and manufactures approximately 90% of its flagship brands locally, according to Asif Alavi, General Manager for North Africa at Haleon. Speaking to Daily News Egypt, Alavi said that local production covers trusted household names such as Sensodyne, Parodontax, Panadol, Otrivin, and Voltaren Emulgel, underscoring Haleon's commitment to supply chain resilience and economic contribution through technology transfer and export capabilities. Egypt serves as a key regional base for exports to the Maghreb, Gulf countries, and Saudi Arabia. Alavi emphasized that local manufacturing has helped shield the company from global economic volatility, including inflation, currency fluctuations, and supply chain disruptions. 'Our strategy has significantly minimized exposure to global shocks, enabling us to maintain stability and accessibility in the Egyptian market,' he noted. Globally, Haleon is advancing its innovation pipeline, including a £130m investment in a new Global Oral Health Innovation Centre in Weybridge, UK, slated to open in 2027. The facility will support Haleon's category leadership in oral health and accelerate R&D for key brands like Sensodyne, which Alavi described as resilient due to its therapeutic value and strong dentist recommendations—even during economic downturns. Recognizing the price sensitivity in emerging markets, Haleon has adopted a multi-format, tiered pricing strategy to ensure broad accessibility. The company also champions self-care as a cornerstone of sustainable healthcare. Alavi cited research by the Global Self-Care Federation, which estimates self-care interventions have already delivered $119bn in global healthcare cost savings and $1.9trn in welfare gains—figures projected to rise to $179bn and $2.8trn, respectively. Looking ahead, Alavi reaffirmed Haleon's long-term vision in Egypt: 'We are committed to being a core contributor to the Egyptian healthcare ecosystem—by making everyday health more accessible, inclusive, and sustainable.'
Mid East Info
05-05-2025
- Business
- Mid East Info
Özlem Kaynak to lead Haleon's Middle East and Africa Operations as Region Prioritizes Self-Care - Middle East Business News and Information
Dubai, United Arab Emirates, May, 2025: Haleon, a global leader in consumer healthcare and home to brands including Panadol, Sensodyne, Parodontax, Voltaren, Otrivin, and Centrum, has named Özlem Kaynak as its new General Manager for the Middle East & Africa (MEA) Business Unit, effective May 1st. This appointment highlights Haleon's commitment to strengthening its leadership team and global market presence. Özlem's appointment comes at a time when the Middle East and Africa region is placing a growing emphasis on self-care and preventive health, in alignment with Haleon's commitment to delivering accessible health solutions to consumers. Based in Haleon's MEA regional hub office in Dubai, she will be responsible for driving the company's growth strategies and enhancing operations across more than 45 countries. These include Turkey, the Gulf & Near East (including the United Arab Emirates and adjoining countries), Pakistan, Kenya, South Africa, Egypt, and Saudi Arabia and others. Formerly overseeing the Central Eastern Europe (CEE) cluster including Romania, Hungary, Slovakia and Czech Republic. Özlem holds over 25 years of experience in the industry; her previous roles include positions at GSK Consumer Healthcare, Omega Pharma Perrigo, and NIVEA Beiersdorf, where she gained expertise in general management, marketing, and sales. 'I am thrilled to take on the responsibility of leading Haleon MEA — a strategically important region for driving global healthcare innovation,' commented Kaynak. 'I am particularly eager to collaborate with our partners and stakeholders to advance the health inclusivity agenda, ensuring that everyone feels empowered to prioritize their everyday health. I look forward to working with our teams as we support the region's wider healthcare ambitions and national well-being strategies.' Özlem's role will be focused on deepening market presence and unlocking equitable access to better everyday health for all. Her appointment reaffirms Haleon's efforts to increase the representation of women in leadership roles in healthcare. About Haleon: Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax and Centrum – are built on trusted science, innovation and deep human understanding.
Reuters
30-04-2025
- Business
- Reuters
Haleon first-quarter organic revenue growth beats estimates
April 30 (Reuters) - British consumer healthcare group Haleon's (HLN.L), opens new tab first-quarter organic revenue growth beat expectations on Wednesday as strong growth in oral health products offset weakness in respiratory health and digestive health products. Organic revenue for the three months ending March 31 grew 3.5%, and analysts were expecting a growth of 3.2%, according to a company-compiled consensus. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Growing demand for Haleon's oral hygiene products, which includes Sensodyne and Parodontax, helped cushion the impact of lower revenue from its respiratory health and digestive health portfolio that include products like Otrivin and ENO. Haleon reaffirmed its 2025 guidance and said it continues to expect the macroeconomic environment to remain "challenging and uncertain".
